Sentence examples for final mean dose from inspiring English sources

The final mean dose in these critically ill ICU patients was 0.24 ± 0.16 μg/kg/min (min, 0.02 μg/kg/min; max, 0.48 μg/kg/min).

Subjects treated with insulin glargine (final mean dose of insulin glargine achieved was 33.7 units) experienced a greater reduction in fasting plasma glucose and weight gain (2.1 kg).

The final mean dose in these critically ill patients was 0.24 ± 0.16 μg/kg/min, which is about one eighth of the usually recommended dose and even markedly lower than the previously suggested dose for critically ill ICU patients.

Reservations have been expressed with regard to the latter study because the final mean dose of insulin glargine (25 IU/day) was relatively low, even though it was titrated to maintain fasting plasma glucose <5.6 mmol/l.

The final mean dose in these critically ill ICU patients was 0.33, about one-sixth of the usually recommended dose, probably reflecting the degree of illness and that there was a tendency to target the lower end of the therapeutic aPTT range.

Final mean daily dose for immediate release methylphenidate ranged from 0.8 mg/kg -1.12 mg/kg except for the study by Wang et al. which used a final dose range of 0.2-0.6 0.2-0.6

The final mean (SD) divalproex dose and serum valproic acid level were 2309 +/- 507 mg/d and 82 +/- 30 mg/L, respectively.

The lower dose in that study [ 13] may be partly explained by lower baseline HbA1c and BMI than for patients in the present study where the final mean insulin glargine dose (38.7 IU/day) was comparable with other studies [ 18, 22].

In the study which compared atomoxetine with standard treatment, only data for patients who received methylphenidate as their initial treatment was included in the analysis [ 20]. *atomoxetine slow metabolisers **atomoxetine rapid metabolisers 18 mg OROS MPH = 15 mg IR MPH The final mean daily atomoxetine dose used in the trials ranged from 1.28 mg/kg-1.56 mg/kg.

Patients with neuropathic pain, incidental pain, as well as the presence of psychological distress or addiction, required a higher final mean morphine equivalent daily dose (MEDD) (P < 0.001).

The mean baseline dose was 0.21 U/kg for both insulin types, and the mean dose at final visit was 0.30 U/kg for insulin detemir and 0.31 U/kg for insulin glargine.